Peter is going to talk about a very straightforward, simple epidemiologic paper, that he thinks has important significance Originally he had gone down the rabbit hole on a much more nuanced paper at ATP binding cassettes in cholesterol absorption Ultimately, he thought this paper might be more interesting to a broader audience Peter had a dream about Andrew last night In this dream, Andrew was obsessed with making a certain drink that was like his elixir It had all of these crazy ingredients in it, tons of supplements When Peter woke up, he was trying hard to remember them One thing it had in it was dew Andrew had to collect a certain amount of dew off the leaves every morning to put into this drink The best part: Andrew had a thermos of this stuff that had to be with him everywhere All of his clothes had to be tailored with a special pocket that he could put the thermos into so that he was never without this special drink Andrew replies, Well, its not that far from reality, Im a big fan of yerba mate

Effectiveness is a critical consideration when evaluating any medication change
While the SAFE Drugs Act remains under legislative consideration, the FDA and state attorneys general appear to already be implementing more aggressive oversight measures until a more stringent oversight framework is in place
Although Rybelsus contains the same active ingredient as Wegovy, they are technically not licensed for the same thing
April 8, 2025: MDL Against Ozempic and Other GLP-1s Top 1,600 in April As of April 1, 2025, there are 1,685 active lawsuits pending against Novo Nordisk and other pharmaceutical companies that sold GLP-1 drugs like Ozempic